📊 IPSC Key Takeaways
Is IPSC a Good Investment? Thesis Analysis
Century Therapeutics is a pre-commercial biotech company with significant revenue growth but severe profitability challenges and deteriorating financial health. While exceptional revenue growth (+1556.8% YoY) and strong liquidity suggest successful commercialization, the company is burning cash at an unsustainable rate (-$104.7M FCF) with negative operating margins (-15.8%) and a widening cash burn runway despite asset base.
Why Buy IPSC? Key Strengths
- Exceptional revenue growth of 1556.8% YoY indicates successful market entry and product adoption
- Strong balance sheet with $61.9M cash and minimal debt (0.07x debt-to-equity), providing runway
- Excellent liquidity position with 5.97x current ratio ensures no immediate solvency concerns
IPSC Investment Risks to Consider
- Massive operating cash burn of -$103.9M annually is unsustainable and will exhaust cash reserves within 6-8 quarters
- Company remains deeply unprofitable with negative operating margins (-15.8%) and operating losses of -$17.3M despite revenue growth
- Free cash flow of -$104.7M with -95.9% FCF margin demonstrates business model has not achieved unit economics or scaling efficiency
- Negative interest coverage (-32.0x) indicates inability to service debt from operations if liquidity deteriorates
Key Metrics to Watch
- Operating cash burn rate and cash runway timeline to profitability or funding needs
- Path to positive operating margins as revenue scales - currently growing revenue without profitability improvement
- Gross margin realization once available - critical to understanding long-term unit economics sustainability
IPSC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.97x current ratio provides a solid financial cushion.
IPSC Profitability Ratios
IPSC vs Healthcare Sector
How Century Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IPSC Overvalued or Undervalued?
Based on fundamental analysis, Century Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IPSC Balance Sheet & Liquidity
IPSC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Century Therapeutics, Inc.'s revenue has grown significantly by 2,000% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.61 indicates the company is currently unprofitable.
IPSC Growth Metrics (YoY)
IPSC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $791.0K | $9.6M | $0.11 |
| Q2 2025 | $771.0K | -$28.1M | $-0.38 |
| Q1 2025 | $855.0K | -$28.1M | $-0.45 |
| Q3 2024 | $148.0K | -$28.1M | $-0.37 |
| Q2 2024 | $99.0K | -$28.1M | $-0.38 |
| Q1 2024 | $855.0K | -$28.1M | N/A |
| Q3 2023 | $148.0K | -$30.7M | $-0.53 |
| Q2 2023 | $99.0K | -$31.0M | $-0.54 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IPSC Capital Allocation
IPSC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Century Therapeutics, Inc. (CIK: 0001850119)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 26, 2026 | 8-K | tm269823d1_8k.htm | View → |
| Mar 16, 2026 | 4 | xslF345X05/form4-03162026_080351.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/form4-03162026_080350.xml | View → |
| Mar 13, 2026 | 4 | xslF345X05/form4-03132026_080321.xml | View → |
| Mar 13, 2026 | 4 | xslF345X05/form4-03132026_080344.xml | View → |
❓ Frequently Asked Questions about IPSC
What is the AI rating for IPSC?
Century Therapeutics, Inc. (IPSC) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IPSC's key strengths?
Claude: Exceptional revenue growth of 1556.8% YoY indicates successful market entry and product adoption. Strong balance sheet with $61.9M cash and minimal debt (0.07x debt-to-equity), providing runway.
What are the risks of investing in IPSC?
Claude: Massive operating cash burn of -$103.9M annually is unsustainable and will exhaust cash reserves within 6-8 quarters. Company remains deeply unprofitable with negative operating margins (-15.8%) and operating losses of -$17.3M despite revenue growth.
What is IPSC's revenue and growth?
Century Therapeutics, Inc. reported revenue of $109.2M.
Does IPSC pay dividends?
Century Therapeutics, Inc. does not currently pay dividends.
Where can I find IPSC SEC filings?
Official SEC filings for Century Therapeutics, Inc. (CIK: 0001850119) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IPSC's EPS?
Century Therapeutics, Inc. has a diluted EPS of $-0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IPSC a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Century Therapeutics, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IPSC stock overvalued or undervalued?
Valuation metrics for IPSC: ROE of -6.0% (sector avg: 15%), net margin of -8.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IPSC stock in 2026?
Our dual AI analysis gives Century Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IPSC's free cash flow?
Century Therapeutics, Inc.'s operating cash flow is $-103.9M, with capital expenditures of $848.0K. FCF margin is -95.9%.
How does IPSC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.8% (avg: 12%), ROE -6.0% (avg: 15%), current ratio 5.97 (avg: 2).